Posted by Michael Wonder on 23 Nov 2020
AB201 development as a potential treatment for COVID-19 receives U.S. FDA fast track designation
23 November 2020 - AB201 is the only novel compound being developed for COVID associated coagulopathy.
ARCA Biopharma today announced that the U.S. FDA has designated as a fast track development program the investigation of AB201 as a potential treatment for COVID-19.
The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalised with COVID-19 in December 2020, with top-line trial data anticipated in the second quarter of 2021.
